the management of hypertension in hemodialysis patients
DESCRIPTION
The Management of Hypertension In Hemodialysis Patients. Dr. Abdulkareem Alsuwaida Associate Professor King Saud University. Hemodialysis Symposium 08-09 February 2014 Al Madinah AlMunawwarah. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: The Management of Hypertension In Hemodialysis Patients](https://reader035.vdocument.in/reader035/viewer/2022081511/568157cf550346895dc5552d/html5/thumbnails/1.jpg)
Dr. Abdulkareem AlsuwaidaAssociate Professor King Saud University
Hemodialysis Symposium08-09 February 2014
Al Madinah AlMunawwarah
![Page 2: The Management of Hypertension In Hemodialysis Patients](https://reader035.vdocument.in/reader035/viewer/2022081511/568157cf550346895dc5552d/html5/thumbnails/2.jpg)
Iseki et al. Ther Apher Dial 2007;11:183-188
![Page 3: The Management of Hypertension In Hemodialysis Patients](https://reader035.vdocument.in/reader035/viewer/2022081511/568157cf550346895dc5552d/html5/thumbnails/3.jpg)
SYSTOLIC BLOOD PRESSURE mm HgSYSTOLIC BLOOD PRESSURE mm Hg
stro
ke d
eath
sst
roke
dea
ths
Hea
rt d
eath
sH
eart
dea
ths
StrokeStroke
168168<120<120 125125 135135 148148
22
44
88
1616
3232
HeartHeart
168 168
120120 125125 135135 148148
1616
88
44
22
11
![Page 4: The Management of Hypertension In Hemodialysis Patients](https://reader035.vdocument.in/reader035/viewer/2022081511/568157cf550346895dc5552d/html5/thumbnails/4.jpg)
Stidley et al. J Am Soc Nephrol 2006;17:513-520
Unadjusted survival by baseline predialysis systolic BP
![Page 5: The Management of Hypertension In Hemodialysis Patients](https://reader035.vdocument.in/reader035/viewer/2022081511/568157cf550346895dc5552d/html5/thumbnails/5.jpg)
“Reverse-epidemiology”Low BP is a consequence of other disease:
Major CVDMalnutrition-inflammation-atherosclerosis
complexLVD
![Page 6: The Management of Hypertension In Hemodialysis Patients](https://reader035.vdocument.in/reader035/viewer/2022081511/568157cf550346895dc5552d/html5/thumbnails/6.jpg)
Mechanism of HTNSodium and volume overload.Sympathetic nervous system activityInappropriate renin secretion.Alteration in endothelin and nitric oxide.Erythropoietin therapy.Hyperparathyroidism.Other:
Uremic toxins, Nocturnal hypoxemia and sleep disturbances
Nephrol Dial Transplant. 2004 May; 19(5):1058-68
![Page 7: The Management of Hypertension In Hemodialysis Patients](https://reader035.vdocument.in/reader035/viewer/2022081511/568157cf550346895dc5552d/html5/thumbnails/7.jpg)
Mechanism of HTNHypervolemia is the major factorPositive Sodium balance
Increases intake and decreased excretion Achieving DW will control 60% of cases of
HTNAssessment of DW
Am J Kidney Dis. 1996 Aug; 28(2):257-61
![Page 8: The Management of Hypertension In Hemodialysis Patients](https://reader035.vdocument.in/reader035/viewer/2022081511/568157cf550346895dc5552d/html5/thumbnails/8.jpg)
Mechanism of HTNRenin inappropriately high for ? etiology.
Increase vascular resistanceIncreased in sympathetic activity
Originate from kidneys Uremic metabolites that activate chemoreceptors
within the kidney Increase vascular resistance and systemic BP
![Page 9: The Management of Hypertension In Hemodialysis Patients](https://reader035.vdocument.in/reader035/viewer/2022081511/568157cf550346895dc5552d/html5/thumbnails/9.jpg)
When and How to measure the BP in dialysis patients?Dialysis Unit: During, Before, or AfterHome BPABPM
![Page 10: The Management of Hypertension In Hemodialysis Patients](https://reader035.vdocument.in/reader035/viewer/2022081511/568157cf550346895dc5552d/html5/thumbnails/10.jpg)
When and How to measure the BP in dialysis patients?Predialysis SBP overestimated mean SBP by
an average of 10 mm HgPostdialysis SBP underestimated mean SBP
by an average of 7 mm HgBP reasings over a period of 1 to 2 weeks
rather than isolated readings should be used
![Page 11: The Management of Hypertension In Hemodialysis Patients](https://reader035.vdocument.in/reader035/viewer/2022081511/568157cf550346895dc5552d/html5/thumbnails/11.jpg)
Alborzi et al. CJASN 2007;2:1228-1234
![Page 12: The Management of Hypertension In Hemodialysis Patients](https://reader035.vdocument.in/reader035/viewer/2022081511/568157cf550346895dc5552d/html5/thumbnails/12.jpg)
When and How to measure the BP in dialysis patients?Interdialytic ABP monitoring best represent
BP in dialysis patients.Only method that will show diurnal variation Difficult to repeat, Vascular access
Home BP
![Page 13: The Management of Hypertension In Hemodialysis Patients](https://reader035.vdocument.in/reader035/viewer/2022081511/568157cf550346895dc5552d/html5/thumbnails/13.jpg)
Relationship between BP and mortality in dialysis patients
Luther JM Kidn Int 2008;73:667-668
![Page 14: The Management of Hypertension In Hemodialysis Patients](https://reader035.vdocument.in/reader035/viewer/2022081511/568157cf550346895dc5552d/html5/thumbnails/14.jpg)
Target blood pressure?Scarcity of evidencePre-dialysis BP < 150/90
ABPM < 140/85 Avoid drop of SBP greater than 30 mm Hg or
post dialysis postural hypotension. Increase mortality and hospitalization
< 110/60 mm Hg correlates significantly with the risk of death within 5 years
Kidney Int 2007;71: 454–61. Kidney Int 2004;66:1212–20. Am J Kidn Dis. 2005;45
![Page 15: The Management of Hypertension In Hemodialysis Patients](https://reader035.vdocument.in/reader035/viewer/2022081511/568157cf550346895dc5552d/html5/thumbnails/15.jpg)
ABPM systolic BP and mortality.
Agarwal R Hypertension. 2010;55:762-768
![Page 16: The Management of Hypertension In Hemodialysis Patients](https://reader035.vdocument.in/reader035/viewer/2022081511/568157cf550346895dc5552d/html5/thumbnails/16.jpg)
Management of Hypertension Step 1: Lifestyle modifications and control of
volume status with lifestyle modifications.Step 2: Control of volume status with dialysis.Step 3: Administration of antihypertensive
drugs.
![Page 17: The Management of Hypertension In Hemodialysis Patients](https://reader035.vdocument.in/reader035/viewer/2022081511/568157cf550346895dc5552d/html5/thumbnails/17.jpg)
Life style modifications Body weight:
'obesity paradox‘ Mainly explained by mal-or undernutrition.
Low salt intake 1000 to 1500 mg of sodium/day
Exercise
![Page 18: The Management of Hypertension In Hemodialysis Patients](https://reader035.vdocument.in/reader035/viewer/2022081511/568157cf550346895dc5552d/html5/thumbnails/18.jpg)
Life style modifications Tobacco use
59% more CHF68% more PVDMortality 37%
Foley et al. Kidney Int 2003; 63: 1462-7.
![Page 19: The Management of Hypertension In Hemodialysis Patients](https://reader035.vdocument.in/reader035/viewer/2022081511/568157cf550346895dc5552d/html5/thumbnails/19.jpg)
Life style modifications
![Page 20: The Management of Hypertension In Hemodialysis Patients](https://reader035.vdocument.in/reader035/viewer/2022081511/568157cf550346895dc5552d/html5/thumbnails/20.jpg)
Management of Hypertension Control of volume status Limit interdialytic weight gain
a 2.5 kg is associated with a significant increase in BP
Achieve dry weightFrequent dialysis & Longer dialysis time
Agarwal R, et al. Hypertension. 2009 Mar; 53(3):500-7.
![Page 21: The Management of Hypertension In Hemodialysis Patients](https://reader035.vdocument.in/reader035/viewer/2022081511/568157cf550346895dc5552d/html5/thumbnails/21.jpg)
Dry WeightCriteria to determining DW:No marked fall in BP during dialysis.No hypertension (predialysis BP at the
beginning of the week <140/90 mm Hg).No peripheral edema.No pulmonary congestion on chest X-ray.Cardiothoracic ratio ≤50% (≤53% in
females).
![Page 22: The Management of Hypertension In Hemodialysis Patients](https://reader035.vdocument.in/reader035/viewer/2022081511/568157cf550346895dc5552d/html5/thumbnails/22.jpg)
Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial.
Agarwal R, et al. Hypertension. 2009 Mar; 53(3):500-7.
![Page 23: The Management of Hypertension In Hemodialysis Patients](https://reader035.vdocument.in/reader035/viewer/2022081511/568157cf550346895dc5552d/html5/thumbnails/23.jpg)
Antihypertensive drugs160/95 mmHg immediate before the next
dialysis session Campese VM TA. Hypertension in dialysis
patients. 2004.
All classes of antihypertensive can be used in dialysis patients (Except diuretics).
Compelling indications are similar
![Page 24: The Management of Hypertension In Hemodialysis Patients](https://reader035.vdocument.in/reader035/viewer/2022081511/568157cf550346895dc5552d/html5/thumbnails/24.jpg)
Treatment of Hypertension ARBs and ACE are the preferable first line of
antihypertensive drugsPrevent left ventricular hypertrophy
Cannella G etal.Am J Kidney Dis. 1997 Nov; 30(5):659-64.Suzuki H et al. Am J Kidney Dis. 2008 Sep; 52(3):501-6.
![Page 25: The Management of Hypertension In Hemodialysis Patients](https://reader035.vdocument.in/reader035/viewer/2022081511/568157cf550346895dc5552d/html5/thumbnails/25.jpg)
Pharmacokinetic properties of ACE Inhibitors in ESRDT1/2(h)
normal
T1/2(h)
ESRD
Initial dose in
HD
Maintenance dose in HD
Removal during HD
Captopril 2-3 20-30 12.5 q24h 25-50 q24h Yes
Enalapril 11 prolonged 2.5 q24h or q48h
2.5-10 q24h or q48h
Yes
Fosinopril 12 prolonged 10 q24h 10-20 q24h Yes
Lisinopril 13 54 2.5 q24h or q48h
2.5-10 q24h or q48h
Yes
Ramipril 11 prolonged 2.5-5q24h 2.5-10 q24h yes
Henrich W. Principles and Practice of Dialysis
![Page 26: The Management of Hypertension In Hemodialysis Patients](https://reader035.vdocument.in/reader035/viewer/2022081511/568157cf550346895dc5552d/html5/thumbnails/26.jpg)
Pharmacokinetic properties of ARB’s in ESRD
T1/2(h)
normal
T1/2(h)
ESRD
Initial dose in HD
Maintenance dose in HD
Removal during HD
Candesartan 9 ? 4 q24h 8-32 q24h No
Irbesartan 11-15 11-15 75-150 q24h 150-300 q24h No
Losartan 2 4 50 q24h 50-100 q24h No
Telmisartan 24 ? 40 q24h 20-80 q24h No
Valsartan 6 ? 80 q24h 80-160 q24h No
Henrich W. Principles and Practice of Dialysis
![Page 27: The Management of Hypertension In Hemodialysis Patients](https://reader035.vdocument.in/reader035/viewer/2022081511/568157cf550346895dc5552d/html5/thumbnails/27.jpg)
Pharmacologic properties of β-blockers in chronic dialysis patients
T1/2(h)
normal
T1/2(h)
ESRD
Initial dose in HD
Maintenance dose in HD
Removal during HD
Acebutolol 3.5 3.5 200 q24h 200-300 q24h yes
Atenolol 6-9 <120 25 q48h 25-50 q48h Yes
Carvedilol 4-7 4-7 5 q24h 5 q24h no
Metoprolol 3-4 3-4 50 b.i.d. 50-100 b.i.d. high
Propranolol 2-4 2-4 40 b.i.d. 40-80 b.i.d. yes
Henrich W. Principles and Practice of Dialysis
![Page 28: The Management of Hypertension In Hemodialysis Patients](https://reader035.vdocument.in/reader035/viewer/2022081511/568157cf550346895dc5552d/html5/thumbnails/28.jpg)
Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. Agarwal R et al NDT 2014
ESRD with LVHlisinopril (n = 100) or atenolol (n = 100) each
administered three times per week after dialysis.
Results:Hospitalizations for heart failure were worse in
the lisinopril group (IRR 3.13, P = 0.021). All-cause hospitalizations were higher in the
lisinopril group [IRR 1.61 (95% CI 1.18-2.19, P = 0.002)].
![Page 29: The Management of Hypertension In Hemodialysis Patients](https://reader035.vdocument.in/reader035/viewer/2022081511/568157cf550346895dc5552d/html5/thumbnails/29.jpg)
• Blood pressure remaining above goal in spite of concurrent use of 3 antihypertensive agents of different classes.
Resistant Hypertension
![Page 30: The Management of Hypertension In Hemodialysis Patients](https://reader035.vdocument.in/reader035/viewer/2022081511/568157cf550346895dc5552d/html5/thumbnails/30.jpg)
Resistant HTN in ESRD Transdermal clonidine at weekly intervals.Minoxidil, a potent vasodilator,
used with beta blockers
Spironolactone in Hemodialysis Patients 25-50 mg post dialysis Risk of hyperkalemiaImprove EF and Improve BP control Large studies are done
![Page 31: The Management of Hypertension In Hemodialysis Patients](https://reader035.vdocument.in/reader035/viewer/2022081511/568157cf550346895dc5552d/html5/thumbnails/31.jpg)
Resistant HypertensionThe use of non steroidal anti-inflammatory
drugsRenovascular hypertensionIncreasing cysts in polysystic kidney diseaseCompliance
![Page 32: The Management of Hypertension In Hemodialysis Patients](https://reader035.vdocument.in/reader035/viewer/2022081511/568157cf550346895dc5552d/html5/thumbnails/32.jpg)
Resistant HTN in ESRD Renal sympathetic nerve ablation
Hyperactivation of the sympathetic nervous system
J Clin Hypertens (Greenwich). 2012 Nov;14
The Future?Device-Based Therapy for Resistant
Hypertension Baroreflex Activation Therapy Renal Denervation Therapy
![Page 33: The Management of Hypertension In Hemodialysis Patients](https://reader035.vdocument.in/reader035/viewer/2022081511/568157cf550346895dc5552d/html5/thumbnails/33.jpg)
Baroreflex Activation Therapy (BAT)Continuously Modulates the Autonomic Nervous System
HR Vasodilation Natriuresis Renin secretion
![Page 34: The Management of Hypertension In Hemodialysis Patients](https://reader035.vdocument.in/reader035/viewer/2022081511/568157cf550346895dc5552d/html5/thumbnails/34.jpg)
Anatomical Location of Renal Sympathetic Nerves
Arise from T10-L1Follow the renal
artery to the kidneyPrimarily lie within
the adventitia
The Journal of Clinical Hypertension. 14, pages 799–801,2012Circulation. 2002;106:1974–1979
![Page 35: The Management of Hypertension In Hemodialysis Patients](https://reader035.vdocument.in/reader035/viewer/2022081511/568157cf550346895dc5552d/html5/thumbnails/35.jpg)
![Page 36: The Management of Hypertension In Hemodialysis Patients](https://reader035.vdocument.in/reader035/viewer/2022081511/568157cf550346895dc5552d/html5/thumbnails/36.jpg)
Intradialytic hypertension 5-15%Mechanism
Extracellular volume overload Increased cardiac output Changes in sodium levels Activation of the renin–angiotensin–aldosterone
system Overactivity of the sympathetic nervous system Endothelial cell dysfunction. Removal of anti HTN during dialysis
![Page 37: The Management of Hypertension In Hemodialysis Patients](https://reader035.vdocument.in/reader035/viewer/2022081511/568157cf550346895dc5552d/html5/thumbnails/37.jpg)
Intradialytic Hypertension The most important treatment is adequate
sodium and water removal and reducing sympathetic hyperactivity.
Changing to non-dialyzable antihypertensive medications
Altering the dialysis prescription.
![Page 38: The Management of Hypertension In Hemodialysis Patients](https://reader035.vdocument.in/reader035/viewer/2022081511/568157cf550346895dc5552d/html5/thumbnails/38.jpg)
Summary Sodium excess and extracellular volume
expansion is the major factor in the development of hypertension.
Lifestyle modifications is critical.Control of volume status (Dietary salt and
fluid restriction).Correcting adequately volume expansion with
dialysis.All classes of antihypertensive drugs can be
used in dialysis patients
![Page 39: The Management of Hypertension In Hemodialysis Patients](https://reader035.vdocument.in/reader035/viewer/2022081511/568157cf550346895dc5552d/html5/thumbnails/39.jpg)
Thank YouThank You